FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751576284> ?p ?o ?g. }

• W2751576284 abstract "The recently developed reagent, eribulin mesylate (eribulin), is a microtubule dynamics inhibitor with a mechanism of action that differs from those of taxanes and vinca alkaloids. This drug is considered to be a promising chemotherapeutic agent for the treatment of locally advanced or metastatic breast cancer (MBC). In this study, we investigated if variables such as tumor expression of β-tubulin class III, glutathione S-transferase pi (GSTP) 1 or transducin-like enhancer of split (TLE) 3 might act as predictive factors on the therapeutic effect of eribulin chemotherapy.The subjects included 52 patients with MBC who underwent chemotherapy with eribulin. The expression levels of Estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor (HER) 2, Ki67, β-tubulin class III, GSTP-1 and TLE-3 were evaluated using immunostaining employing needle biopsy specimens.Patients with TLE3-negative tumors displayed significantly poorer outcomes regarding progression-free survival than patients with TLE3-positive tumors when prognosis within the group of patients with triple-negative breast cancer (TNBC) lesions was analyzed (p = 0.011, log-rank). In contrast, no such difference in prognosis was found in a comparison of TLE-3 positive/negative patients in the group of all patients (p = 0.433, log-rank) or of patients with non-TNBC lesions (p = 0.659, log-rank). Based on a univariate analysis of 22 TNBC cases, a better progression-free survival correlated significantly with a positive TLE3 expression in the tumor (p = 0.025). A multivariate logistic regression analysis including 22 patients with TNBC also showed that a positive TLE3 expression significantly correlated with a better progression-free survival (p = 0.037).Our findings suggest that TLE3 is a useful marker for predicting the therapeutic effect of eribulin chemotherapy for TNBC." @default.
• W2751576284 created "2017-09-15" @default.
• W2751576284 creator A5010201656 @default.
• W2751576284 creator A5017393726 @default.
• W2751576284 creator A5032903747 @default.
• W2751576284 creator A5041423375 @default.
• W2751576284 creator A5053084872 @default.
• W2751576284 creator A5074337807 @default.
• W2751576284 creator A5077160140 @default.
• W2751576284 creator A5084684329 @default.
• W2751576284 creator A5085519388 @default.
• W2751576284 creator A5086848779 @default.
• W2751576284 creator A5088294268 @default.
• W2751576284 date "2017-08-31" @default.
• W2751576284 modified "2023-10-15" @default.
• W2751576284 title "Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer" @default.
• W2751576284 cites W1542114385 @default.
• W2751576284 cites W1916389172 @default.
• W2751576284 cites W1971579914 @default.
• W2751576284 cites W1973942156 @default.
• W2751576284 cites W1974570521 @default.
• W2751576284 cites W1995224853 @default.
• W2751576284 cites W1996055575 @default.
• W2751576284 cites W2019607817 @default.
• W2751576284 cites W2025982636 @default.
• W2751576284 cites W2028092386 @default.
• W2751576284 cites W2030055085 @default.
• W2751576284 cites W2034121120 @default.
• W2751576284 cites W2040914426 @default.
• W2751576284 cites W2044702943 @default.
• W2751576284 cites W2051483759 @default.
• W2751576284 cites W2051878959 @default.
• W2751576284 cites W2059272061 @default.
• W2751576284 cites W2063012393 @default.
• W2751576284 cites W2063478423 @default.
• W2751576284 cites W2080442030 @default.
• W2751576284 cites W2097255042 @default.
• W2751576284 cites W2097398235 @default.
• W2751576284 cites W2098514397 @default.
• W2751576284 cites W2099335989 @default.
• W2751576284 cites W2102838762 @default.
• W2751576284 cites W2105712639 @default.
• W2751576284 cites W2109142047 @default.
• W2751576284 cites W2122544830 @default.
• W2751576284 cites W2123851255 @default.
• W2751576284 cites W2126559635 @default.
• W2751576284 cites W2127152525 @default.
• W2751576284 cites W2131994307 @default.
• W2751576284 cites W2132049943 @default.
• W2751576284 cites W2132445915 @default.
• W2751576284 cites W2133858286 @default.
• W2751576284 cites W2136662615 @default.
• W2751576284 cites W2138941973 @default.
• W2751576284 cites W2142221925 @default.
• W2751576284 cites W2157840751 @default.
• W2751576284 cites W2168577971 @default.
• W2751576284 cites W2259802687 @default.
• W2751576284 cites W2586608125 @default.
• W2751576284 cites W2739785379 @default.
• W2751576284 cites W4239380575 @default.
• W2751576284 cites W4292079585 @default.
• W2751576284 doi "https://doi.org/10.1186/s12885-017-3598-5" @default.
• W2751576284 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5580315" @default.
• W2751576284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28859615" @default.
• W2751576284 hasPublicationYear "2017" @default.
• W2751576284 type Work @default.
• W2751576284 sameAs 2751576284 @default.
• W2751576284 citedByCount "14" @default.
• W2751576284 countsByYear W27515762842018 @default.
• W2751576284 countsByYear W27515762842019 @default.
• W2751576284 countsByYear W27515762842021 @default.
• W2751576284 countsByYear W27515762842022 @default.
• W2751576284 countsByYear W27515762842023 @default.
• W2751576284 crossrefType "journal-article" @default.
• W2751576284 hasAuthorship W2751576284A5010201656 @default.
• W2751576284 hasAuthorship W2751576284A5017393726 @default.
• W2751576284 hasAuthorship W2751576284A5032903747 @default.
• W2751576284 hasAuthorship W2751576284A5041423375 @default.
• W2751576284 hasAuthorship W2751576284A5053084872 @default.
• W2751576284 hasAuthorship W2751576284A5074337807 @default.
• W2751576284 hasAuthorship W2751576284A5077160140 @default.
• W2751576284 hasAuthorship W2751576284A5084684329 @default.
• W2751576284 hasAuthorship W2751576284A5085519388 @default.
• W2751576284 hasAuthorship W2751576284A5086848779 @default.
• W2751576284 hasAuthorship W2751576284A5088294268 @default.
• W2751576284 hasBestOaLocation W27515762841 @default.
• W2751576284 hasConcept C121608353 @default.
• W2751576284 hasConcept C126322002 @default.
• W2751576284 hasConcept C143998085 @default.
• W2751576284 hasConcept C144301174 @default.
• W2751576284 hasConcept C2775930923 @default.
• W2751576284 hasConcept C2776387010 @default.
• W2751576284 hasConcept C38180746 @default.
• W2751576284 hasConcept C530470458 @default.
• W2751576284 hasConcept C71924100 @default.
• W2751576284 hasConceptScore W2751576284C121608353 @default.
• W2751576284 hasConceptScore W2751576284C126322002 @default.
• W2751576284 hasConceptScore W2751576284C143998085 @default.
• W2751576284 hasConceptScore W2751576284C144301174 @default.
• W2751576284 hasConceptScore W2751576284C2775930923 @default.

• next